First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis—results from a multicenter prospective randomized controlled trial and its post hoc analysis
Authors
Keywords
Ulcerative colitis, Infliximab, Therapeutic drug monitoring, Primary response, Mucosal healing
Journal
JOURNAL OF GASTROENTEROLOGY
Volume 51, Issue 3, Pages 241-251
Publisher
Springer Nature
Online
2015-07-10
DOI
10.1007/s00535-015-1102-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Levels of Drug and Antidrug Antibodies Are Associated With Outcome of Interventions After Loss of Response to Infliximab or Adalimumab
- (2015) Henit Yanai et al. Clinical Gastroenterology and Hepatology
- An Accelerated Infliximab Induction Regimen Reduces the Need for Early Colectomy in Patients With Acute Severe Ulcerative Colitis
- (2015) David J. Gibson et al. Clinical Gastroenterology and Hepatology
- The microbiota in inflammatory bowel disease
- (2015) Donal Sheehan et al. JOURNAL OF GASTROENTEROLOGY
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications
- (2014) Jason R. Goldsmith et al. JOURNAL OF GASTROENTEROLOGY
- Review article: strategies for the management of chronic unremitting ulcerative colitis
- (2013) S. J. Mehta et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Infliximab in Steroid-dependent Ulcerative Colitis
- (2013) Alessandro Armuzzi et al. INFLAMMATORY BOWEL DISEASES
- Efficacy, safety, and predictors of response to infliximab therapy for ulcerative colitis: A Korean multicenter retrospective study
- (2013) Kang-Moon Lee et al. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
- The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure
- (2013) S. B. Krintel et al. RHEUMATOLOGY
- Anti-TNF Monoclonal Antibodies in Inflammatory Bowel Disease: Pharmacokinetics-Based Dosing Paradigms
- (2012) I Ordás et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Anti-infliximab antibodies in inflammatory bowel disease
- (2012) Lennard Y.W. Lee et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial
- (2012) David Laharie et al. LANCET
- Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis
- (2011) Jean Frédéric Colombel et al. GASTROENTEROLOGY
- Guidelines for the management of inflammatory bowel disease in adults
- (2011) C. Mowat et al. GUT
- Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis
- (2011) A.A. Fasanmade et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started